Estimating the budget impact of orphan medicines in Europe: 2010 - 2020

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Schey, Carina ^a   Milanova, Tsveta ^b   Hutchings, Adam ^a  

^a GMAS LLP   (United Kingdom)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; ORPHAN DRUG; DRUG;

ARTICLE; B CELL LEUKEMIA; BUDGET; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EUROPE; GAUCHER DISEASE; HUMAN; ONCOLOGY; ORPHAN DISEASE; PATENT; PREDICTION; PREVALENCE; RARE DISEASE; UNITED KINGDOM; DRUG MANUFACTURE; ECONOMICS; HEALTH CARE POLICY; LEGAL ASPECT; MARKETING;

BUDGETS; DRUG APPROVAL; DRUG COSTS; EUROPE; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; MARKETING; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; PREVALENCE; RARE DISEASES;

EID: 80053379101     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-62     Document Type: Article

References (26)

1. Orphan drugs and rare diseases at a glance. European Medicines Agency (EMA), http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/01/ WC500069805.pdf Last accessed 01/02/2011. Doc. Ref. EMEA/290072/2007.
2. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Disease: Europe's Challenges. European Commission, http://ec.europa.eu/health/ph-threats/non-com/docs/rare-com-en.pdf Last accessed 01/02/2011. Brussels, 11.11.2008.
3. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. European Parliament, http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF 22.01.2000.
4. Register of designated Orphan Medicinal Products. European Commission (Directorate General Health & Consumers), http://ec.europa.eu/health/ documents/community-register/html/orphreg.htm
5. Eurordis survey on orphan drugs availability in Europe. Bignami F, Presented at the 6th Eurordis Round Table of Companies Workshop. Barcelona 9 July 2007 http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf
6. A comparative study of European rare disease and orphan drug markets. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S, Health Policy 2010 97 173 179 10.1016/j.healthpol.2010.05.017 20800761
7. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. McCabe C, EJHP 2010 16 4 22 24
8. Open letter to prime minister David Cameron and health secretary Andrew Lansley. Nicholl D, Hilton-Jones D, Palace J, Richmond S, Finlayson S, Winer J, Weir A, Maddison P, Fletcher N, Sussman J, Silver N, Nixon J, Kullman D, Embleton N, Beeson D, Farrugia ME, Hill M, McDermott C, Llewelyn G, Leonard J, Morris M, BMJ 2010 341 6466 10.1136/bmj.c6466 21081599
9. Study of Orphan Drugs. De Varax A, Letellier M, Börtlein G, Alcimed 2004 http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final-final- report-part-1-web-en.pdf
10. Price Setting Orphan Drugs: Identifying the influential factors on the price setting of Orphan Drugs. van Ekdom l, 2007 http://www.uu.nl/uupublish/ content/Ekdom-Liselore-van-eindverslag.pdf
11. Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007. Orofino J, Soto J, Casado MA, Oyagüez I, Appl Health Econ Health Policy 2010 8; 5 301 315 21892840
12. Belgian Health Care Knowledge Centre. Policies for Rare Diseases and Orphan Drugs. Belgian Federal Centre for Healthcare, KCE Report 112C 2009 Also published as: Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Journal of Medical Economics. 2010, 13; 2: 295-301
13. Arzneiverordnungsreport. Schwabe U, Paffrath D, 2010 http://www.springer. com/pharma/book/978-3-642-13379-4
14. Orphanet: Prevalence of rare diseases: bibliographic data. Orphanet Report Series (1). Paris 2010
15. Inventory of Access and Prices of Orphan Drugs across Europe: A Collaborative Work between National Alliances on Rare Diseases & Eurordis. Le Cam Y, Paris 2010
16. Orphan drug development is not taking off. Joppi R, Bertele V, Garattini S, British Journal of Clinical Pharmacology 2009 67 5 494 502 10.1111/j.1365-2125.2009.03369.x 19552743
17. Association of British Pharmaceutical Industry. http://www.abpi.org.uk/ our-work/value-access/groups/Pages/omig.aspx
18. Pharmaceutical Sector Inquiry-Final Report. Fact Sheet 1: Prices, time to generic entry and consumer savings. European Commission, 2008 http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/fact-sheet-1.pdf
19. The Pharmaceutical Industry in Figures: 2010 Edition. European Federation of Pharmaceutical Industries and Associations (EFPIA), 2010 http://www.efpia.eu/content/default.asp?PageID=559&DocID=9158
20. Market Prognosis. IMS Health, 2010
21. European Pharmaceutical Review. http://www.europeanpharmaceuticalreview. com/news/industry-news/ims-forecasts-global-pharmaceutical-market-growth-of-5-8- annually-through-2014-maintains-expectations-of-4-6-growth-in-2010
22. GIST Data sign a setback for Tasigna against Glivec as giant Novartis axes trial. Scrip, 2011 http://www.scripintelligence.com/researchdevelopment/ GIST-data-sign-a-setback-for-Tasigna-against-Glivec-as-giant-Novartis-axes- trial-313895
23. Actelion hit by negative Tracleer data. Scrip, 2010 http://www. scripintelligence.com/researchdevelopment/Actelion-hit-by-negative-Tracleer- data-188980
24. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Tambuyzer E, Nature Reviews Drug Discovery 2010 9 12 921 9 10.1038/nrd3275 21060315
25. Practice guidelines for the therapy of essential thrombocythaemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S, Haematological 2004 2 215 232 (Pubitemid 38796497)
26. Anagrelide Summary of Product Characteristics. http://www.medicines.org. uk/emc/medicine/15737/SPC/Xagrid+0.5mg+hard+capsule/